NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines.

With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

Edinburgh, GB
16 (est)

Key People at NuCana

Chris Wood

Chris Wood

Executive Chairman & Medical Director
Hugh S. Griffith

Hugh S. Griffith

Co-Founder, CEO & Board Member
Ian Abercrombie

Ian Abercrombie

Business Unit Director

NuCana Locations

Edinburgh, GB

NuCana Metrics

NuCana Summary

Founding Date


Total Funding

$67.5 M

Latest funding size

$57 M

Time since last funding

over 2 years


NuCana Company Life